Results 11 to 20 of about 5,495 (171)

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine [PDF]

Frontiers in Pharmacology, 2022
Epilepsy is among the most common neurological chronic disorders, with a prevalence of 0.5–1%. Despite the introduction of new antiepileptic drugs during recent years, about one third of the epileptic population remain drug-resistant.
Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell’Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Pasquale Striano, Alberto Verrotti   +7 more
doaj   +2 more sources

Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome

Epilepsy & Behavior Reports, 2021
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented to our hospital in November 2018 in super-refractory status epilepticus.
David Millett, Suzanne Pach
doaj   +3 more sources

A review of fenfluramine for the treatment of Dravet syndrome patients

Current Research in Pharmacology and Drug Discovery, 2022
Introduction: Dravet Syndrome (DS) is a rare epileptiform disorder typically presenting within the first year of life of a normally developing infant. It is characterized by several prolonged seizures that are often resistant to current anti-epileptic ...
Kayla Simon, Hunter Sheckley, Christopher L. Anderson, Zhao Liu, Paul R. Carney   +4 more
doaj   +2 more sources

Effect of fenfluramine on seizures and comorbidities in SCN8A‐developmental and epileptic encephalopathy: A case series [PDF]

Epilepsia Open, 2022
SCN8A‐developmental and epileptic encephalopathy is caused by pathogenic variants in the SCN8A gene encoding the Nav1.6 sodium channel, and is characterized by intractable multivariate seizures and developmental regression.
Ángel Aledo‐Serrano, Borja Cabal‐Paz, Elena Gardella, Pablo Gómez‐Porro, Otilia Martínez‐Múgica, Alvaro Beltrán‐Corbellini, Rafael Toledano, Irene García‐Morales, Antonio Gil‐Nagel   +8 more
doaj   +2 more sources

Fenfluramine increases survival and reduces markers of neurodegeneration in a mouse model of Dravet syndrome [PDF]

Epilepsia Open
Objective In patients with Dravet syndrome (DS), fenfluramine reduced convulsive seizure frequency and provided clinical benefit in nonseizure endpoints (e.g., executive function, survival).
John Cha, Gregory Filatov, Steven J. Smith, Arnold R. Gammaitoni, Amélie Lothe, Thadd Reeder   +5 more
doaj   +2 more sources

Hormonal response during a fenfluramine-associated panic attack [PDF]

Brazilian Journal of Medical and Biological Research, 1997
Secretion curves for prolactin, cortisol, TSH, and GH from a 37-year old woman with dysthymia and panic disorder with agoraphobia were determined one day prior to (day I), and during a panic attack (day II) associated with an oral dose of 60 mg dl ...
A.H.G. Vieira, R.T. Ramos, V. Gentil
doaj   +2 more sources

Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome [PDF]

Epilepsia Open
Objective To assess the efficacy and tolerability of fenfluramine (FFA) with concomitant potassium bromide (BR) in patients with Dravet syndrome (DS).
Milka Pringsheim, Gerhard Kluger, Adam Strzelczyk, Susanne Schubert‐Bast, Thomas Mayer, Benjamin Glauche, Hiltrud Muhle, Michael Alber, Hartwig Spors, Tilmann Polster, Regina Trollmann, Gerhard Kurlemann, Markus Berndt, Kerstin A. Klotz   +13 more
doaj   +2 more sources

Effects of low-doses of methamphetamine on d-fenfluramine-induced head-twitch response (HTR) in mice during ageing and c-fos expression in the prefrontal cortex

BMC Neuroscience, 2023
Background The head-twitch response (HTR) in mice is considered a behavioral model for hallucinogens and serotonin 5-HT2A receptor function, as well as Tourette syndrome in humans.
Yina Sun, Seetha Chebolu, Stone Skegrud, Setareh Kamali, Nissar A. Darmani   +4 more
doaj   +1 more source

Efficacy and safety of fenfluramine in the treatment of Dravet syndrome - literature review

Journal of Education, Health and Sport, 2022
Dravet Syndrome is a severe, drug-resistant, and rare epileptiform disorder that is typically presented in the first year of life in an otherwise healthy child. It is characterized by prolonged seizures that are often resistant to current anti-epileptic
Martyna Stefaniak, Zofia Pietrzak, Piotr Dzikowski, Emilia Nowicka, Michał Obel, Halina Piecewicz-Szczęsna   +5 more
doaj   +1 more source

Fenfluramine: a plethora of mechanisms?

Frontiers in Pharmacology, 2023
Developmental and epileptic encephalopathies are rare, treatment-resistant epilepsies with high seizure burden and non-seizure comorbidities. The antiseizure medication (ASM) fenfluramine is an effective treatment for reducing seizure frequency ...
Jo Sourbron, Lieven Lagae
doaj   +1 more source